Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation (BTD) for poziotinib and expects a

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 1, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.S.

Veteran of the Biopharmaceutical Industry Joins as Company Advances Two Late-stage Oncology Therapies HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 18, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 27, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Spectrum will host a live webcast today at 4:30 p.m. Eastern/1:30 p.m. Pacific HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 24, 2018-- Spectrum Pharmaceuticals, Inc.

Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations Phase 2 study now includes four cohorts with each cohort being an independent study with pre-specified statistical hypotheses

The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 30, 2018-- Spectrum Pharmaceuticals, Inc.  (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 2, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

ADVANCE, first Phase 3 study, met the non-inferiority of ROLONTIS to pegfilgrastim endpoint in the Duration of Severe Neutropenia (DSN) across all 4 cycles (all p

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 25, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday,

HENDERSON, Nev. --(BUSINESS WIRE)--May 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

Primary endpoint of non-inferiority of ROLONTIS to pegfilgrastim was met All secondary endpoints were met Adverse events were similar between ROLONTIS and pegfilgrastim ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a propriety technology HENDERSON,

HENDERSON, Nev. --(BUSINESS WIRE)--May 9, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy

Enrollment completed in MD Anderson’s 50 patient EGFR exon 20 mutation cohort for poziotinib in non-small cell lung cancer. Nature Medicine publication reported a confirmed objective response rate of 64 percent in the first 11 patients with EGFR exon 20 mutations treated with poziotinib.

HENDERSON, Nev. --(BUSINESS WIRE)--May 3, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo